ATNM Actinium Pharmaceuticals, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1388320 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY130.6%
TTM EPS YoY130.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE55.2%
ROA23.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.20x
Accruals ratio76.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $35.00M | — | $0 | $90,000 | — | — | — |
| R&D expense | $4.71M | $5.38M | $4.20M | $4.30M | $4.25M | $4.88M | $7.70M | $4.81M |
| SG&A expense | $1.42M | $2.06M | $1.70M | $2.12M | $1.53M | $2.62M | $8.94M | $2.69M |
| Operating income | -$6.12M | $27.57M | -$5.90M | -$6.41M | -$5.69M | -$7.50M | -$16.64M | -$7.50M |
| Net income | -$5.84M | $27.90M | -$5.52M | -$5.94M | -$5.13M | -$6.88M | -$15.94M | -$6.65M |
| EBITDA | -$5.90M | $28.00M | -$5.87M | -$6.86M | -$5.49M | -$7.30M | -$16.59M | -$7.92M |
| EPS (basic) | -0.19 | 0.89 | -0.18 | — | -0.16 | -0.22 | -0.51 | — |
| EPS (diluted) | -0.19 | 0.89 | -0.18 | — | -0.16 | -0.22 | -0.51 | — |
| Weighted avg. shares (diluted) | 31.44M | 31.41M | 31.24M | — | 31.20M | 31.20M | 31.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $28.68M | $36.47M | $42.13M | $48.00M | $53.72M | $60.26M | $65.65M | $73.23M |
| Current assets | $29.49M | $37.74M | $43.26M | $49.38M | $54.37M | $61.03M | $66.46M | $74.51M |
| PP&E, net | $1.45M | $700,000 | $268,000 | $295,000 | $226,000 | $271,000 | $317,000 | $364,000 |
| Total assets | $32.47M | $40.16M | $45.44M | $51.77M | $56.15M | $63.02M | $68.65M | $76.90M |
| Current liabilities | $7.37M | $9.26M | $7.35M | $7.97M | $6.83M | $8.31M | $7.11M | $8.15M |
| Total liabilities | $7.88M | $9.86M | $43.13M | $43.94M | $42.37M | $44.00M | $42.95M | $44.14M |
| Shareholders' equity | $24.59M | $30.30M | $2.30M | $7.83M | $13.78M | $19.01M | $25.69M | $32.76M |
| Shares outstanding | 31.44M | 31.44M | 31.37M | 31.20M | 31.20M | 31.20M | 31.20M | 31.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.02M | -$5.18M | -$5.87M | -$5.29M | -$6.33M | -$5.39M | -$7.57M | -$5.75M |
| Capital expenditure | $770,000 | $478,000 | $2,000 | — | — | — | — | $0 |
| Free cash flow | -$7.79M | -$5.66M | -$5.87M | — | — | — | — | -$5.75M |
| Investing cash flow | -$770,000 | -$478,000 | -$2,000 | — | — | — | — | $0 |
| Financing cash flow | -$3,000 | -$2,000 | -$3,000 | -$3,000 | -$209,000 | -$3,000 | -$2,000 | -$3,000 |
| Depreciation & amortization | $218,000 | $432,000 | $29,000 | -$442,000 | $206,000 | $204,000 | $47,000 | -$410,000 |
| Stock-based compensation | $136,000 | $118,000 | $11,000 | $10,000 | $109,000 | $197,000 | $8.87M | $1.20M |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.